<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="6176">
  <stage>Registered</stage>
  <submitdate>9/11/2015</submitdate>
  <approvaldate>9/11/2015</approvaldate>
  <nctid>NCT02604225</nctid>
  <trial_identification>
    <studytitle>Trial of Methoxyflurane With Periprostatic Local Anaesthesia to Reduce the Discomfort of TRUS B</studytitle>
    <scientifictitle>A Phase 3 Double-blind Placebo-controlled Randomized Trial of Methoxyflurane With Periprostatic Local Anaesthesia to Reduce the Discomfort of Transrectal Ultrasound-guided Prostate Biopsy</scientifictitle>
    <utrn />
    <trialacronym>TRUSB</trialacronym>
    <secondaryid>ACTRN12615001105538</secondaryid>
    <secondaryid>ANZUP 1501</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Cancer</healthcondition>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Methoxyflurane
Treatment: drugs - Placebo

Experimental: Penthrox - Methoxyflurane

Placebo Comparator: Placebo - Saline 0.9%


Treatment: drugs: Methoxyflurane
Participants randomised to the experimental arm will inhale methoxyflurane administered through the Penthrox® inhaler starting approximately one minute before insertion of the rectal probe.

Treatment: drugs: Placebo
Participants randomised to the control arm will inhale 0.9% saline administered through the Penthrox® inhaler starting approximately one minute before insertion of the rectal probe.

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Pain rated by participants will be self-rated using a numeric rating scale with verbal anchors from 0 (no trouble at all) to 10 (worst I can imagine).</outcome>
      <timepoint>Pain will be assessed at 15 minutes after the TRUS biopsy</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Other aspects of the biopsy experience rated by participants on the Patient's Experience of TRUS biopsy questionnaire.</outcome>
      <timepoint>Rated at 15 minutes after the biopsy</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Other aspects of the biopsy experience rated by participants on the Patient's Experience of TRUS biopsy questionnaire.</outcome>
      <timepoint>Rated at 7-35 days after the biopsy</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Willingness to undergo a biopsy in the future assessed by a questionnaire designed specifically for this study.</outcome>
      <timepoint>Rated at 15 minutes and 7-35 days after the biopsy</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Urologist's ratings of the participant's biopsy experience, assessed by a questionnaire</outcome>
      <timepoint>On the same day as the TRUS biopsy</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Biopsy completion rate.</outcome>
      <timepoint>Recorded on day of TRUS biopsy.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Frequency of specified adverse events.</outcome>
      <timepoint>Adverse events will be recorded after the TRUS biopsy (before the participant leaves the clinic), and 7-35 days after the biopsy.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Frequency of hospitalisation by reviewing hospital records.</outcome>
      <timepoint>Details will be recorded for each emergency department visit and each non-elective hospital admission that occurs within 30 days of the TRUS biopsy.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. Males older than 18 years scheduled to undergo a TRUS biopsy of the prostate.

          2. Adequate liver function: ALT, AST, or bilirubin = 2 x ULN

          3. Adequate renal function: serum eGFR&gt; 30 ml/min/1.73m2

          4. Willing and able to complete questionnaires in English

          5. Willing and able to undergo TRUS biopsy within 7 days of randomisation

          6. Willing and able to comply with all study requirements, including treatment, timing
             and/or nature of required assessments

          7. Signed, written informed consent</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Male</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. Previous TRUS biopsy of the prostate

          2. Personal or family history of malignant hyperthermia

          3. History of significant liver disease

          4. Hypersensitivity to fluorinated anaesthetics or other inhalational anaesthetics

          5. Concurrent use of barbiturates or tetracycline antibiotics

          6. Concurrent illness that may jeopardise the ability of the patient to undergo the
             procedures outlined in this protocol with reasonable safety

          7. Presence of any psychological, familial, sociological or geographical condition
             potentially hampering compliance with the study protocol and follow-up schedule,
             including alcohol dependence or drug abuse.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/12/2015</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>420</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/12/2017</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,VIC,WA</recruitmentstate>
    <hospital>Concord Hospital - Concord</hospital>
    <hospital>Australian Clinical Trials - Wahroonga</hospital>
    <hospital>Casey Hospital - Berwick</hospital>
    <hospital>The Alfred Hospital - Prahran</hospital>
    <hospital>Fiona Stanley Hospital - Murdoch</hospital>
    <hospital>Westmead Hospital - Westmead</hospital>
    <postcode>2640 - Concord</postcode>
    <postcode>2640 - Wahroonga</postcode>
    <postcode> - Berwick</postcode>
    <postcode> - Prahran</postcode>
    <postcode> - Murdoch</postcode>
    <postcode> - Westmead</postcode>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Christchurch</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>University of Sydney</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Australian and New Zealand Urogenital and Prostate Cancer Trials Group</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>A phase 3 double-blind placebo-controlled randomized trial of methoxyflurane with
      periprostatic local anaesthesia to reduce the discomfort of transrectal ultrasound-guided
      prostate biopsy (Pain-Free TRUS B).</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02604225</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Jeremy Grummet</name>
      <address>Principal Investigator</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Claudia Bishop</name>
      <address />
      <phone />
      <fax />
      <email>trusb@ctc.usyd.edu.au</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>